Estimating treatment effects for individual patients based on the results of randomised clinical trialsJannick A N Dorresteijn, Nancy R. Cook, Frank L.J. Visseren et al.|BMJ|2011Cited by 178
C-Reactive Protein and Risk of Incident Heart Failure in Patients With Cardiovascular DiseaseP.M. Burger, Stefan Koudstaal, Arend Mosterd et al.|Journal of the American College of Cardiology|2023Cited by 134
Prediction of individualized lifetime benefit from cholesterol lowering, blood pressure lowering, antithrombotic therapy, and smoking cessation in apparently healthy peopleN E M Jaspers, Jannick A N Dorresteijn|European Heart Journal|2019Cited by 118
C-Reactive Protein and Risk of Cardiovascular Events and Mortality in Patients with Various Cardiovascular Disease LocationsP.M. Burger, Frank L.J. Visseren, Martin Teraa et al.|The American Journal of Cardiology|2023Cited by 66
Course of the effects of LDL-cholesterol reduction on cardiovascular risk over time: A meta-analysis of 60 randomized controlled trialsP.M. Burger, Frank L.J. Visseren, Jannick A N Dorresteijn et al.|Atherosclerosis|2024Cited by 36